Neurology
RSSArticles
-
Pharmacology Update: Perampanel Tablets (Fycompa)
The FDA has approved the first in class α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor antagonist for the treatment of seizures. Perampanel is an orally active noncompetitive AMPA antagonist. The drug is marketed by Eisai Inc. as Fycompa. -
Pharmacology Update: Brimonidine Tartrate Topical Gel (Mirvaso®)
A highly selective alpha-2 adrenergic receptor agonist has been approved by the FDA for the treatment of persistent facial erythema of rosacea in adults. -
Azithromycin — The Heart of the Matter Redux: Pre-existing Risks Tell the Tale
Svanström and colleagues in copenhagen examined the risk of cardiovascular deaths in association with azithromycin use in a nationwide historical cohort study of Danish adults aged 18-64 years. -
Internal Medicine Alert - Full September 29, 2013 Issue in PDF
-
Omega 3s and the Prostate: Good or Bad?
The role of omega-3 fatty acids in prostate cancer risk has been inconsistent and it has been difficult to draw practical and clinically useful conclusions from the research. -
Clinical Briefs By Louis Kuritzky
-
Effect of Dabigatran on Referrals to and Switching from Warfarin
Dabigatran has been demonstrated to decrease the rate of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF) by one-third, while also decreasing the rate of intracranial bleeding by two-thirds compared with warfarin. -
Emergency Medicine Reports - Full March 24, 2013 Issue in Streaming Audio/Downloadable MP3 Format
-
Emergency Medicine Reports March 24, 2013 Issue in PDF
-
Treating Pain in Pediatric Patients
It has been 13 years since the Joint Commission on Accreditation of Healthcare Organizations directed hospitals to treat pain as a "fifth vital sign."